Overview

Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The present study proposes to evaluate the potential cognitive enhancing effects of GLYX-13, an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness on a series of functional magnetic resonance imaging (fMRI) learning and memory tasks.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University